Comparative Pharmacology
Head-to-head clinical analysis: AMIKIN versus BRISTAGEN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMIKIN versus BRISTAGEN.
AMIKIN vs BRISTAGEN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Aminoglycoside antibiotic that binds to the 30S ribosomal subunit, causing misreading of mRNA and inhibition of protein synthesis.
Bristagen (amikacin) is an aminoglycoside antibiotic that irreversibly binds to the 30S ribosomal subunit, inhibiting bacterial protein synthesis.
15 mg/kg/day IV or IM divided every 8 to 12 hours; usual adult dose: 15 mg/kg/day
1-2 mg/kg IM or IV every 8-12 hours; typical adult dose is 1 mg/kg every 8 hours.
None Documented
None Documented
2-3 hours in adults with normal renal function; prolonged to 30-90 hours in ESRD.
2.5 hours (prolonged to 20-40 hours in renal impairment).
Renal: >90% unchanged in urine via glomerular filtration; biliary/fecal: <1%.
Renal (90% unchanged via glomerular filtration); biliary/fecal excretion <10%.
Category C
Category C
Aminoglycoside Antibiotic
Aminoglycoside Antibiotic